EUVIMEDEUVIMED entdecken
Crossref

Conditional sequential delivery of ginkgetin and rapamycin orchestrates inflammation and autophagy to alleviate intervertebral disc degeneration

Jiaoxiang Chen, Xin Gan, Shenkai Su, Sizhe Jiao, Zailing Gong, Ziqiang Liu, Xiaopei Wu, Jun Jiang, Jiaming Zhang, Junlai Wan

Journal of Controlled Release · 2025-05 · 381 · 113556

DOI: 10.1016/j.jconrel.2025.02.052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-05. Verfasst von Jiaoxiang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Spine Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, …. Hauptthemen laut MEDLINE: Intervertebral Disc Degeneration, Sirolimus, Anti-Inflammatory Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Southern Medical University, Wenzhou Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intervertebral disc degeneration (IVDD) is a multifaceted and complex condition primarily driven by excessive inflammation, degradation of the extracellular matrix (ECM), and dysfunction of nucleus pulposus cells (NPCs). Despite extensive exploration of various therapeutic agents targeting IVDD, their efficacy remains disappointingly limited. This study underscores the efficacy of ginkgetin (GK), a natural bioflavonoid with potent anti-inflammatory properties, in mitigating inflammation as well as ECM degradation and NPC dysfunction triggered by interleukin-1β (IL-1β). However, GK alone cannot fully address the persistent obstruction in autophagic flux induced by IL-1β. To overcome this limitation, an innovative MMP13-responsive nanoplatform was developed, orchestrating the sequential delivery of GK and rapamycin (RA), targeting distinct phases of IVDD progression. In this design, GK is progressively released from exosomes during the initial phase, while RA is released from mesoporous silica nanoparticles during the mid-phase to enhance autophagic flux. This staged release approach leverages the strengths of both agents, addressing inflammation and restoring autophagy more effectively. In vivo experiments confirmed the substantial therapeutic benefits of this staggered delivery strategy in IVDD. The engineered MMP13-responsive nanoplatform represents a significant advancement in controlled, sequential drug delivery systems, offering a promising therapeutic avenue to effectively regulate inflammation and autophagy, thereby ameliorating IVDD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intervertebral Disc DegenerationSirolimusAnti-Inflammatory AgentsAutophagyAnimalsInflammationNucleus PulposusNanoparticlesHumansMatrix Metalloproteinase 13Interleukin-1betaMaleRats, Sprague-DawleySilicon DioxideDrug Delivery SystemsRats

Stichwörter der Autor:innen

AutophagyExosomeInflammationIntervertebral disc degenerationSequential drug release

Substanzen

SirolimusAnti-Inflammatory AgentsMatrix Metalloproteinase 13Interleukin-1betaSilicon Dioxide

Autor:innen und Institutionen

  • Division of Spine Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China; Department of Orthopedics, the Second Affiliate…
  • Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
  • Department of Orthopedics, the Second Affiliated Hospital and Yuying Children Hospital of Wenzhou Medical University, Wenzhou 325003, China.
  • The First Clinical Medical College, Southern Medical University, Guangzhou 510000, China.
  • Clinical Innovation & Research Center (CIRC), Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China.
  • State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, Wuhan 430070, China.

Förderung

  • Southern Medical University
  • Wenzhou Medical University
  • National Natural Science Foundation of China
  • Huazhong University of Science and Technology
  • National Natural Science Foundation of China-Guangdong Joint Fund

Zitieren

APA

Chen, J., Gan, X., Su, S., Jiao, S., Gong, Z., Liu, Z., Wu, X., Jiang, J., Zhang, J., & Wan, J. (2025). Conditional sequential delivery of ginkgetin and rapamycin orchestrates inflammation and autophagy to alleviate intervertebral disc degeneration. Journal of Controlled Release, 381, 113556. https://doi.org/10.1016/j.jconrel.2025.02.052

Vancouver

Chen J, Gan X, Su S, Jiao S, Gong Z, Liu Z, et al. Conditional sequential delivery of ginkgetin and rapamycin orchestrates inflammation and autophagy to alleviate intervertebral disc degeneration. Journal of Controlled Release. 2025;381:113556. doi:10.1016/j.jconrel.2025.02.052

BibTeX
@article{Chen2025,
  author = {Chen, Jiaoxiang and Gan, Xin and Su, Shenkai and Jiao, Sizhe and Gong, Zailing and Liu, Ziqiang and Wu, Xiaopei and Jiang, Jun and Zhang, Jiaming and Wan, Junlai},
  title = {Conditional sequential delivery of ginkgetin and rapamycin orchestrates inflammation and autophagy to alleviate intervertebral disc degeneration},
  journal = {Journal of Controlled Release},
  year = {2025},
  volume = {381},
  pages = {113556},
  doi = {10.1016/j.jconrel.2025.02.052}
}
Kostenlos starten →